Dual role of α-defensin-1 in anti-HIV-1 innate immunity

Journal of Clinical Investigation

Volumn 115, Issue 3, 2005, Pages 765-773

  Chang, Theresa L ^a,b   Vargas Jr , Jesus ^a   DelPortillo, Armando ^a   Klotman, Mary E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Division of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; ALPHA DEFENSIN; ALPHA DEFENSIN 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; LIFE CYCLE; MOLECULAR MECHANICS; NEUTROPHIL; NUCLEAR IMPORT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 14644425916     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI21948     Document Type: Article

References (60)

1. Hackett, C.J. 2003. Innate immune activation as a broad-spectrum biodefense strategy: prospects and research challenges. J. Allergy Clin. Immunol. 112:686-694.
2. Medzhitov, R., and Janeway, C., Jr. 2000. Innate immunity. N. Engl. J. Med. 343:338-344.
3. Janeway, C.A., Jr., and Medzhitov, R. 2002. Innate immune recognition. Annu. Rev. Immunol. 20:197-216.
4. Boman, H.G. 2003. Antibacterial peptides: basic facts and emerging concepts. J. Intern. Med. 254:197-215.
5. Lehner, T. 2003. Innate and adaptive mucosal immunity in protection against HIV infection. Vaccine. 21(Suppl. 2):S68-S76.
6. Levy, J.A., Scott, I., and Mackewicz, C. 2003. Protection from HIV/AIDS: the importance of innate immunity. Clin. Immunol. 108:167-174.
7. Siegal, F.P., and Spear, G.T. 2001. Innate immunity and HIV. AIDS. 15(Suppl. 5):S127-S137.
8. Kottilil, S., et al. 2003. Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J. Infect. Dis. 187:1038-1045.
9. Mackewicz, C.E., Yang, L.C., Lifson, J.D., and Levy, J.A. 1994. Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. Lancet. 344:1671-1673.
10. Walker, B.D., and Plata, F. 1990. Cytotoxic T lymphocytes against HIV. AIDS. 4:177-184.
11. Carmichael, A., Jin, X., Sissons, P., and Borysiewicz, L. 1993. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J. Exp. Med. 177:249-256.
12. + cell anti-HIV activity correlates with the clinical state of the infected individual. J. Clin. Invest. 87:1462-1466.
13. Cocchi, F., et al. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 270:1811-1815.
14. Zhang, L., et al. 2002. Contribution of human alpha-defensin 1, 2, and 3 to the and-HIV-1 activity of CD8 antiviral factor. Science. 298:995-1000.
15. Chang, T.L., Francois, F., Mosoian, A., and Klotman, M.E. 2003. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. J. Virol. 77:6777-6784.
16. Mackewicz, C.E., et al. 2003. α-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS. 17:F23-F32.
17. Zhang, L., Lopez, P., He, T., Yu, W., and Ho, D.D. 2004. Retraction of an interpretation. Science. 303:467.
18. Lehrer, R.I., Lichtenstein, A.K., and Ganz, T. 1993. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu. Rev. Immunol. 11:105-128.
19. Lehrer, R.I., and Ganz, T. 2002. Defensins of vertebrate animals. Curr. Opin. Immunol. 14:96-102.
20. Yang, D., Biragyn, A., Kwak, L.W., and Oppenheim, J.J. 2002. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 23:291-296.
21. Schonwetter, B.S., Stolzenberg, E.D., and Zasloff, M.A. 1995. Epithelial antibiotics induced at sires of inflammation. Science. 267:1645-1648.
22. Bastian, A., and Schafer, H. 2001. Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul. Pept. 101:157-161.
23. Nakashima, H., Yamamoto, N., Masuda, M., and Fujii, N. 1993. Defensins inhibit HIV replication in vitro. AIDS. 7:1129.
24. Quinones-Mateu, M.E., et al. 2003. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS. 17:F39-F48.
25. Cole, A.M., et al. 2002. Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc. Natl. Acad. Sci. U. S. A. 99:1813-1818.
26. Munk, C., et al. 2003. The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res. Hum. Retroviruses. 19:875-881.
27. Wang, W., Cole, A.M., Hong, T., Waring, A.J., and Lehrer, R.I. 2003. Retrocyclin, an antiretroviral theta-defensin, is a lectin. J. Immunol. 170:4708-4716.
28. Ganz, T. 2003. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3:710-720.
29. Van Wetering, S., Mannesse-Lazeroms, S.P., Dijkman, J.H., and Hiemstra, P.S. 1997. Effect of neutrophil serine proteinases and defensins on lung epithelial cells: modulation of cytotoxicity and IL-8 production. J. Leukoc. Biol. 62:217-226.
30. Lichtenstein, A. 1991. Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. J. Clin. Invest. 88:93-100.
31. Panyutich, A.V., Panyutich, E.A., Krapivin, V.A., Baturevich, E.A., and Ganz, T. 1993. Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. J. Lab. Clin. Med. 122:202-207.
32. Shiomi, K., et al. 1993. Establishment of radioimmunoassay for human neutrophil peptides and their increases in plasma and neutrophil in infection. Biochem. Biophys. Res. Commun. 195:1336-1344.
33. Heine, R.P., Wiesenfeld, H., Mortimer, L., and Greig, P.C. 1998. Amniotic fluid defensins: potential markers of subclinical intrauterine infection. Clin. Infect. Dis. 27:513-518.
34. Maffei, F.A., Heine, R.P., Whalen, M.J., Mortimer, L.F., and Carcillo, J.A. 1999. Levels of antimicrobial molecules defensin and lactoferrin are elevated in the cerebrospinal fluid of children with meningitis. Pediatrics. 103:987-992.
35. Wiesenfeld, H.C., et al. 2002. Association between elevated neutrophil defensin levels and endometririsj. Infect. Dis. 186:792-797.
36. Daher, K.A., Selsted, M.E., and Lehrer, R.I. 1986. Direct inactivation of viruses by human granulocyte defensins. J. Virol. 60:1068-1074.
37. Moore, J.P., and Doms, R.W. 2003. The entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. U. S. A. 100:10598-10602.
38. Hazuda, D.J., et al. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 287:646-650.
39. Charp, P.A., et al. 1988. Inhibition of protein kinase C by defensins, antibiotic peptides from human neutrophils. Biochem. Pharmacol. 37:951-956.
40. Nassar, T., et al. 2002. Human alpha-defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Blood. 100:4026-4032.
41. Fields, A.P., Bednarik, D.P., Hess, A., and May, W.S. 1988. Human immunodeficiency virus induces phosphorylation of its cell surface receptor. Nature. 333:278-280.
42. Lenard, J., Rabson, A., and Vanderoef, R. 1993. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formation. Proc. Natl. Acad. Sci. U. S. A. 90:158-162.
43. Degar, S., et al. 1992. Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating. AIDS Res. Hum. Retroviruses. 8:1929-1936.
44. Keranen, L.M., Dutil, E.M., and Newton, A.C. 1995. Protein kinase C is regulated in vivo by three functionally distinct phosphorylations. Curr. Biol. 5:1394-1403.
45. Zack, J.A., et al. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 61:213-222.
46. Bukrinsky, M.I., et al. 1992. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc. Natl. Acad. Sci. U. S. A. 89:6580-6584.
47. Nabel, G., and Baltimore, D. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature. 326:711-713.
48. Kagnoff, M.F., and Roebuck, K.A. 1999. Human immunodeficiency virus type 1 (HIV-1) infection and expression in intestinal epithelial cells: role of protein kinase A and C pathways in HIV-1 transcription. J. Infect. Dis. 179(Suppl. 3):S444-S447.
49. Han, X.M., Laras, A., Rounseville, M.P., Kumar, A., and Shank, P.R. 1992. Human immunodeficiency virus type 1 Tat-mediated trans activation correlates with the phosphorylation state of a cellular TAR RNA stem-binding factor. J. Virol. 66:4065-4072.
50. Jakobovits, A., Rosenthal, A., and Capon, D.J. 1990. Trans-activation of HIV-1 LTR-directed gene expression by tat requires protein kinase C. EMBO J. 9:1165-1170.
51. Roebuck, K.A., Gu, D.S., and Kagnoff, M.F. 1996. Activating protein-1 cooperates with phorbol ester activation signals to increase HIV-1 expression. AIDS. 10:819-826.
52. Yang, X., Chen, Y., and Gabuzda, D. 1999. ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappaB. J. Biol. Chem. 274:27981-27988.
53. Farnet, C.M., et al. 1998. Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob. Agents Chemother. 42:2245-2253.
54. Lavie, G., et al. 1989. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc. Natl. Acad. Sci. U. S. A. 86:5963-5967.
55. Rabbi, M.F., al-Harthi, L., Saifuddin, M., and Roebuck, K.A. 1998. The cAMP-dependent protein kinase A and protein kinase C-beta pathways synergistically interact to activate HIV-1 transcription in latently infected cells of monocyte/macrophage lineage. Virology. 245:257-269.
56. Kim, C.H., Gollapudi, S., Kim, A., Lee, T., and Gupta, S. 1996. Role of protein kinase C-beta isozyme in activation of latent human immunodeficiency virus type 1 in promonocytic U1 cells by phorbol-12-myristate acetate. AIDS Res. Hum. Retroviruses. 12:1361-1366.
57. Chen, B.K., Saksela, K., Andino, R., and Baltimore, D. 1994. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J. Virol. 68:654-660.
58. Connor, R.I., Sheridan, K.E., Ceradini, D., Choe, S., and Landau, N.R. 1997. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:621-628.
59. Butler, S.L., Johnson, E.P., and Bushman, F.D. 2002. Human immunodeficiency virus cDNA metabolism: norable stability of two-long rerminal repear circles. J. Virol. 76:3739-3747.
60. Cara, A., et al. 2002. Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. Virology. 292:1-5.